Media & Investor Relations
Resources and materials for investors and media
InSitu Biologics
InSitu Biologics, LLC is an emerging drug delivery company focusing on development of new and proprietary treatments using its Matrix™ BioHydrogel. Their lead product, AnestaGel™, is a long-lasting and long-acting non-opiate painkiller, targeted for use in peri-operative regional pain management.
For Media & Press
Please contact
Katie M.
Katie@insitubiologics.com
For Investors
Please contact
Jim Segermark, CEO
Jim@insitubiologics.com
651-337-4799
Pre-Clinical Results
As compared to EXPAREL (Pacira, Inc.), the industry leading post-operative pain treatment.
A Non-Opioid Surgical Analgesic
InSitu Biologics is an emerging drug delivery company focusing on development of new and proprietary treatments using its Matrix™ BioHydrogel. Their lead product, AnestaGel™, is a long-lasting and long-acting non-opiate painkiller, targeted for use in peri-operative regional pain management.
- 22+ US Patents Issued, with matching OUS positions
- Hydrogel technology licensed from Cleveland Clinic Foundation
- Tunable, biocompatible, and pH neutral platform
- High dose drug-load reservoir capacity with a predictable pharmacological effect
- Non-opioid pain relief option




Investment Opportunity
InSitu Biologics intends to launch a Regulation A+ offering to a limited number of investors.
Why Invest
- 22+ US Patents Issued, with matching OUS positions
- Hydrogel technology licensed from Cleveland Clinic Foundation
- Tunable, biocompatible, and pH neutral platform
- High dose drug-load reservoir capacity with a predictable pharmacological effect
- Non-opioid pain relief option
- Early-stage venture opportunity
The Offering
Competitor Market Size
Timeline
-
2015
Q1
Defined the Matrix and AnestaGelQ2
Raised $1 millionQ3
Completed first pre-clinical studyQ4
Analysis showed statistical success compared to Exparel
-
2016
Q1
Filed additional patent(s)Q2
White Paper publishedQ3
Completed maximum dosing study with no toxicityQ4
Presented at PODD-Boston
-
2017
Q1
Completed first GLP studyQ2
Proved more pain relief compared to Exparel in pre-clinical studyQ3
GLP publication acceptedQ4
Raised over $400k
-
2018
Q1
Completed Financial Audit
Converted all debt
Filed $10,000,000 RegA+ OfferingQ2
Launch RegA+ Offering
Announce GLP Paper by Hutchins & TaylorQ3
Announce final GLP Study results
Begin Phase 1 manufacturingQ4
Expect approval for Phase 1 Clinical Study of AnestaGel
Team

James Segermark
CEO
Bill Taylor
Chief Scientist
Daniel Sipple
DO Medical Advisor